Psychedelic Therapy vs Antidepressants: The Real Methodological Challenge Is Unblinding
Why The Comparison Is Harder Than The Headline Suggests
The debate over psychedelic-assisted therapy for depression is often framed as a contest: psychedelics versus antidepressants. In headlines, the question sounds simple. Which works better? Which produces larger reductions in depression scores?
But this comparison is not simple, because the trials behind it are not psychologically equivalent. Traditional antidepressant trials are usually designed as blinded drug-placebo studies. Participants may guess what they are taking, especially if side effects occur, but the trial structure is still built around concealment. Psychedelic trials have a different problem. A full psychedelic dose often produces unmistakable acute subjective effects. For many participants, they know, or strongly suspect, whether they received the active intervention.
This is the issue at the center of the JAMA Psychiatry systematic review and meta-analysis by Williams, Barnett, and Szigeti. The authors asked a sharper methodological question: how does psychedelic-assisted therapy compare with traditional antidepressants under more equal unblinding conditions?
That question changes the meaning of “headline efficacy.” If one intervention is effectively open label and the other is still judged under blinded conditions, a direct comparison may exaggerate the apparent advantage of the less-blinded intervention.
What The Meta-Analysis Actually Compared
The analysis included 24 trials: 8 trials of psychedelic-assisted therapy involving 249 patients and 16 open-label traditional antidepressant trials involving 7,921 patients. The authors also used data from 144 blinded antidepressant trials involving 31,792 patients to examine how open-label versus blinded conditions affected antidepressant outcomes. The main outcome was within-arm improvement from baseline to the primary endpoint on the 17-item Hamilton Depression Rating Scale. This design choice is the key to the paper. Instead of comparing psychedelic-assisted therapy with blinded antidepressant treatment, the authors compared it with open-label antidepressant treatment. Their reasoning was that psychedelic-assisted therapy trials often have high functional unblinding. If patients can usually tell they received a psychedelic, then a fairer comparator may be an antidepressant trial in which patients also know they are receiving active treatment.
The result was less dramatic than many psychedelic narratives might suggest. Psychedelic-assisted therapy was not statistically more effective than open-label traditional antidepressants. The estimated difference was 0.3 HAMD17 points favoring open-label antidepressants, with a confidence interval crossing zero and no statistically significant difference. Once the comparison moved toward equal unblinding, the apparent superiority of psychedelic-assisted therapy largely disappeared.
The study also found that open-label antidepressant trials were associated with slightly greater improvement than blinded antidepressant trials, with an estimated difference of 1.3 HAMD17 points. The same open-label-versus-blinded difference was not observed for psychedelic trials. The authors interpreted this as evidence that psychedelic-assisted therapy trials are, in practical terms, already close to open label.
Why Equal Unblinding Changes The Meaning Of “Efficacy”
Unblinding is sometimes treated as a dry methodological footnote. In depression research, it is more than that. It changes the psychological context in which improvement is measured.
If a patient knows, or strongly believes, that they have received an active intervention, several things can shift at once. Expectancy may rise. The patient may monitor symptoms differently. The therapeutic relationship may feel more charged. Side effects or acute experiences may be interpreted as proof that “something is happening.” Self-reported symptoms may improve partly because the patient feels enrolled in a powerful treatment story.
This does not mean that improvement is fake. Expectancy is not imaginary, and placebo-related improvement can be clinically real. Nor does it mean that psychedelic pharmacology is irrelevant. Psilocybin, MDMA, and other psychedelic or psychedelic-adjacent interventions may have pharmacological and psychological effects that deserve serious study. The point is narrower: if trials are unblinded, the measured effect becomes a mixture of drug effect, therapeutic context, expectancy, and patient interpretation. That mixture is especially important when the outcome is a depression rating scale. Depression trials do not usually measure a hard biological endpoint. They measure changes in mood, sleep, guilt, appetite, anxiety, activity, and suicidal thinking through scales that depend on reporting, interviewing, and interpretation.
The meta-analysis therefore reframes the comparison. The question is not: do psychedelics beat antidepressants when psychedelic trials are functionally open-label and antidepressant trials are mostly blinded? The fairer question is: do psychedelics beat antidepressants when both are studied under conditions where the patient knows, or is likely to know, that active treatment is being given?
Under that condition, the difference looks much smaller. This does not make psychedelic-assisted therapy clinically uninteresting. But it challenges inflated claims that psychedelics are obviously superior to conventional antidepressants based on large cross-trial effect sizes.
It also matters for interpreting recent trials in treatment-resistant depression. If psychedelic trials cannot reliably preserve blinding, then mixed findings should be read with unusual care. The signal may be real. But the mechanism of that signal remains harder to isolate than a headline suggests.
What the Analysis Does Not Prove
The meta-analysis is important, but it should not be overread in the opposite direction. It does not prove that psychedelic-assisted therapy is ineffective. It does not prove that psychedelics and antidepressants are clinically interchangeable. It does not settle questions of durability, remission, functional recovery, relapse prevention, or patient selection. It also does not replace direct head-to-head randomized trials. The analysis compares separate trial literatures, and those literatures differ in important ways. Psychedelic-assisted therapy trials are much smaller. Their populations may differ in treatment history, chronicity, severity, psychotherapy exposure, and baseline expectations. The open-label antidepressant trials included thousands of participants, while the psychedelic-assisted therapy evidence base in this analysis included only 249 patients.
There is also a conceptual limitation. Within-arm change from baseline is not the same as comparative efficacy in a randomized head-to-head design. A patient improving after psychedelic-assisted therapy in one trial and a patient improving after an antidepressant in another trial may not represent the same clinical situation.
So the paper should not be read as “psychedelics do not work.” Its stronger message is methodological: some of the apparent advantage of psychedelic-assisted therapy may shrink when the comparison accounts for blinding integrity.
The Practical Takeaway For Psychedelic Research
The practical takeaway is not that psychedelic-assisted therapy should be abandoned. It is that efficacy claims must be adjusted for blinding.
For researchers, this means future trials should measure and report treatment guesses, expectancy, acute subjective effects, therapeutic alliance, psychotherapy exposure, and functional outcomes. Blinding integrity should not be treated as a minor appendix. It should be part of the main interpretation. If blinding cannot be preserved, trials should acknowledge that directly and build analyses around it.
For clinicians and patients, the message is equally important. Large effect sizes from psychedelic trials may not mean that psychedelics are categorically more powerful than antidepressants. They may partly reflect the fact that psychedelic treatment is difficult to disguise. That does not erase possible benefit, but it does change the confidence with which superiority can be claimed.
The JAMA Psychiatry meta-analysis makes the psychedelic psychiatry debate more honest. Under more equal unblinding conditions, psychedelic-assisted therapy did not outperform open-label traditional antidepressants. That finding should cool exaggerated narratives, but it should not end research. The better conclusion is more disciplined: psychedelic therapy may still become clinically useful for depression, but it must be evaluated with methods that match its unusual psychological and pharmacological profile.
The real methodological challenge is not only showing that patients improve. It is showing why they improve, how much depends on the drug itself, how much depends on the treatment context, and whether the benefit remains meaningful when compared with existing treatments under fair conditions.
References
- Williams, Z. J., Barnett, H., & Szigeti, B. (2026). Psychedelic therapy vs antidepressants for the treatment of depression under equal unblinding conditions: A systematic review and meta-analysis. JAMA Psychiatry, 83(5), 461–468. https://doi.org/10.1001/jamapsychiatry.2025.4809